With a rapidly aging American population (the number of Americans 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050 – an increase of 47%!), primary care optometrists will increasingly be charged with detecting, managing, and treating age-related ocular disease. New innovations in ocular coherence tomography (OCT) technology will have an expanded role in detecting neurodegenerative changes in the eye – form drusen in age related macular degeneration to amyloid plaques in Alzheimer’s disease. In this course we will review the current models and neuropathologic similarities between Alzheimer’s disease and AMD that enable OCT imaging to be a pathway for disease detection today (with AMD) and tomorrow (with Alzheimer’s Disease). We will also discuss new innovations in the treatment of both diseases, with a focus on how doctors should present and discuss the new geographic atrophy treatments in patients with severe non-exudative macular degeneration.